Literature DB >> 23482521

Combined antiplatelet and novel oral anticoagulant therapy after acute coronary syndrome: is three a crowd?

Freek W A Verheugt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23482521     DOI： 10.1093/eurheartj/eht075

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  5 in total

1.  Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation.

Authors:  Rochelle Sweis; José Biller
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-04

2.  Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysis.

Authors:  Yicong Ye; Hongzhi Xie; Yong Zeng; Xiliang Zhao; Zhuang Tian; Shuyang Zhang
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

Review 3.  Neuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutions.

Authors:  Jinlei Li; Thomas Halaszynski
Journal:  Local Reg Anesth       Date:  2015-08-04

4.  New oral anticoagulants in acute coronary syndrome: is there any advantage over existing treatments?

Authors:  Andrea Messori; Valeria Fadda; Roberta Gatto; Dario Maratea; Sabrina Trippoli
Journal:  Int Cardiovasc Res J       Date:  2014-09-01

Review 5.  The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.

Authors:  Marc Cohen; Deepa Iyer
Journal:  Cardiovasc Ther       Date:  2014-10       Impact factor: 3.023
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.